


Delivering New Treatments, Creating Future Smiles



Delivering New Treatments, Creating Future Smiles

Medicine keeps advancing, but many people around the world still suffer from diseases with no cure. A reliable new drug can bring courage for tomorrow to many patients and their families, and also to every healthcare professional who wants to provide the very best treatment. That's what drives us to pioneer new methods, work across disciplines, and bring together all of our strengths. Our aim is to offer courage and strength to all who are waiting for new treatments. Our hope is that every day will continue to be vibrant and healthy for everyone for years to come. Creating a future filled with smiles for all. This is our goal at Taiho Pharmaceutical.

Corporate
Philosophy

**We strive to improve human health
and contribute to a society enriched by smiles.**


Taiho Pharmaceutical is making diverse contributions to sustainability, always working for better health and more smiles for people around the world.





Taiho Pharmaceutical in Numbers

Taiho Pharmaceutical works hard every day to support people's health and bring more smiles to the world. The figures here illustrate the uniqueness of Taiho Pharmaceutical's businesses and strengths as a company.



Countries Where LONSURF
Has Been Approved

93 Countries and Regions

(as of Dec. 2020)

LONSURF, a drug discovered by Taiho Pharmaceutical, was launched in 2014 as a treatment for colorectal cancer. It has been approved in 93 countries and regions around the world. In 2019, an additional indication for gastric cancer was obtained in Japan, the U.S., and Europe, and this indication has now been approved in over 60 countries and regions worldwide.



Oncology Products

72.1% of Sales (2020)

Oncology products account for a large proportion of Taiho Pharmaceutical's sales: 72.1% of ¥140.1 billion. While taking on the challenge of creating anticancer drugs with diverse mechanism of action leveraging its strengths in oncology, Taiho Pharmaceutical also works on developing novel drugs in the fields of allergy/immunology and urology.



R&D Expenses to Net Sales

26.6% (2020)

Taiho Pharmaceutical focuses on in-house drug discovery, allocating 26.6% of its sales to R&D expenses for new drugs. In its ongoing pursuit of research and development of innovative new drugs that can support people's health worldwide, the company leverages its network, which goes beyond research institutions in Japan to include the U.S., Europe, and other parts of Asia.

Percentage of Employees Taking Childcare Leave

Women **100%** Men **77.1%**
(2020)

The percentage of women taking childcare leave is 100%. The percentage of men taking leave is increasing year by year. Taiho Pharmaceutical provides support for employees to balance work with raising children. This includes both systems and facilities, such as interviews during pregnancy, before maternity leave, and before returning from childcare leave, subsidies for babysitting expenses, and an on-site daycare center in the Tsukuba Area.



Pioneering Oral Anticancer Drugs

Since **1974**

In 1974, when oral anticancer drugs were still uncommon, Taiho Pharmaceutical launched Futraful, an oral tegafur formulation. Since then, the company has launched a series of oral anticancer drugs developed in-house: UFT, TS-1, and LONSURF.

Sales of Tiovita Drink Series

Approx. **140,000,000**
bottles/year (2020)

Tiovita Drink is a nutritive energy drink which represents the company's Consumer Healthcare Business. A long-seller since 1964, it sells approximately 140 million bottles per year, for a cumulative total of up to 6.2 billion bottles over the years.


History of Taiho Pharmaceutical

Taiho Pharmaceutical has been in the business of pharmaceuticals (prescription drugs), including anticancer drugs, since its early days in the 1960s. Beginning with Tiovita Drink, its business also includes consumer healthcare products that can be purchased at pharmacies and drug stores. All along, Taiho Pharmaceutical has focused on these two businesses, both closely connected to people's health and smiles.

Looking toward global expansion, especially in ASEAN countries, Taiho Pharmaceutical will continue to research and develop new and unique products that meet people's needs and enrich their lives.

History of the Consumer Healthcare Business

Taiho Pharmaceutical meets people's needs and supports healthy, fulfilling lifestyles with products such as the Tiovita series, the Solmack series, and Harnicare.



History of Pharmaceutical Business (Anticancer Drug Development)

Encountering Futraful: The Beginning of Our Anticancer Drug Development

In 1969, Taiho Pharmaceutical's first president, Yukio Kobayashi, visited the former Soviet Union for business discussions. While there, he encountered Futraful, a derivative* of a novel anticancer drug, 5-fluorouracil (5-FU) created in Latvia. Kobayashi sensed its great potential. He instantly decided to conduct clinical trials in Japan, and the company succeeded in development after overcoming many hurdles. In 1974, the oral anticancer drug Futraful, which enabled long-term oral administration, was developed together with an injectable. Futraful enabled outpatient therapy due to its long-term oral administration, later leading to the establishment of the concept of adjuvant chemotherapy.

*Derivative: A compound created by a change in part of a molecule of a given compound.



1969
Yukio Kobayashi shaking hands with Futraful developer

Pursuing the Advancement of Anticancer Drugs: Overcoming Various Challenges

In 1984, Taiho Pharmaceutical launched UFT, a combination of uracil with Futraful. Having moved forward with research, in 1999, the company launched TS-1, which combined gimeracil and oteracil potassium, with Futraful, the principal component.



1974
Futraful capsule and Futraful injection launched in Japan

Pioneering the Future of Cancer Treatment: Continuing to Improve Patients' Quality of Life

In 2013, Taiho Pharmaceutical launched TS-1 as the world's first anticancer agent in orally disintegrating (OD) tablet form. This helps to improve the quality of life of patients since it can be taken with or without water. In recent years, Taiho Pharmaceutical has been conducting R&D aimed at comprehensive care in oncology, including cancer supportive care.

2013
TS-1 combination OD tablet launched in Japan



2000



2014
LONSURF combination tablet launched in Japan


1999

TS-1 combination capsule launched in Japan



Leveraging extensive evidence and a wealth of experience gained over half a century of anticancer drug development, Taiho Pharmaceutical will continue to develop new drugs that contribute to cancer patients around the world.

2020



Delivering Innovative Drugs from Japan: Making a Difference in Over 90 Countries Worldwide

In its pursuit of global development of new drugs that can contribute to cancer treatment, Taiho Pharmaceutical discovered the anticancer drug LONSURF. LONSURF, a combination of two compounds, trifluridine and tipiracil, was initially launched in Japan in 2014, and the following year it became the company's first U.S. FDA-approved product. In 2016, it was approved by the European Commission and spread around the world. LONSURF has been approved in more than 90 countries, including countries in Asia, and sales are growing.

Taiho Pharmaceutical's Strengths

Drug Discovery

One of Taiho Pharmaceutical's great strengths is its ability to create innovative new drugs using its unique drug discovery platforms. Within the Otsuka Group, Taiho Pharmaceutical has an important role in oncology and takes on the challenge of creating therapeutics for significant unmet needs such as cancers with brain metastasis and those with RAS mutations. The company is also advancing drug discovery research in the area of allergy/immunology by applying technologies emerging from its cancer research. In addition, Taiho Pharmaceutical is pursuing external research collaboration in and outside Japan and has built its own network with biotech ventures and academia (universities and research institutions) to obtain innovative drug-discovery technologies and drug seeds, in order to supplement its own technologies and accelerate R&D.



Percentage of In-house Drug Discovery in Taiho Pharmaceutical's Pipeline

(as of March 2021)


Approx. **81%**

Compounds in development 16

Drugs discovered in-house 13 (approx. 81%)

Oncology products 10

Creating Innovative New Drugs



Creating New Drug Candidates: With Close Collaboration and Using World-Class Drug-Discovery Platforms

The driver of Taiho Pharmaceutical's high percentage of in-house drug discovery is the close collaboration among its departments and researchers, which together represent extensive knowledge and experience in their specialties. The company has also focused on developing and expanding platform technologies related to drug-discovery. It has built its own drug-discovery platform technologies such as the Cysteinomix Drug Discovery Platform and the RAS Drug Discovery Platform, which have gained international recognition. Taiho Pharmaceutical has succeeded in creating a development pipeline of new drug candidates one after another by employing these technologies.

Leveraging External Collaboration to Accelerate R&D: Meeting the Needs of Patients Awaiting New Drugs

Taiho Pharmaceutical strategically employs alliances with external partners to enhance its R&D capabilities, seeking to deliver new drugs to patients suffering from diseases with no effective treatment. The company works with an R&D network in Japan as well as Otsuka group companies, other pharmaceutical companies, and academia in the U.S., Europe, and Asia to supplement its own technologies and development pipeline and to speed up research and development.

Supporting and Collaborating with Biotech Ventures: Expanding the Potential for Future New Drugs

Via two corporate venture capital firms – Taiho Ventures, LLC, established in 2016, and Taiho Innovations, LLC, established in 2019 – Taiho Pharmaceutical invests in and supports biotech ventures and startups around the world that are engaged in innovative new drug R&D. The company aims to gain new perspectives and ideas and create innovations that will expand the potential for the new drugs of the future by accessing original drug-discovery technologies and seeds in these companies and networks.

Employee Voice



Toshiyasu Shimomura, Ph.D.
 Director, Strategic Research Planning & Management

Overcoming High Hurdles in Pursuit of Drug Discovery to Contribute to Better Treatment

I feel honored and privileged to be a researcher every time the drugs we have discovered in the laboratory show benefits in clinical trials and I actually feel that they are contributing to the treatment of cancer in patients. However, in order to meet medical needs for which drug discovery is challenging, such as intractable cancers, we have to overcome many serious hurdles. This is why we are strengthening our research capabilities and actively working with internal and external partners, academia, other pharmaceutical companies, and biotech ventures, to further propel our drug discovery.



Learn more about drug discovery



Product Pipeline



Taiho Pharmaceutical's Strengths

Human Resources

Handling pharmaceuticals means coming face to face with life itself. Taiho Pharmaceutical's basic policy is, "Drug making starts with developing people." The company aims to develop human resources with a high sense of ethics and multifaceted sensibilities, people with knowledge of pharmaceuticals and skills in business execution who are ready to take on new challenges boldly. By offering new employee training and other diverse educational programs, the company provides a rich curriculum that includes opportunities to develop self-awareness as an employee of a company closely involved with human life, to acquire professional expertise, and improve communication skills in medical settings.

Systems Supporting Taiho Pharmaceutical's Human Resources

Master MRs*—internally certified MRs

(as of March 2021) *MR: Medical Representative

160

Academic Experts

11

Correspondence course fee support system

(subsidizes 70% of course fees)

Used by
approx.

500

employees
annually

Earning Trust in Medical Settings: Developing MRs With a Positive Approach to Life

Internal certification system

In order to develop human resources capable of providing and gathering the latest treatment information to and from medical professionals, Taiho Pharmaceutical conducts internal certifications every year in two categories – Master MRs, who combine knowledge about cancer with the ability to make proposals from the patient’s point of view, and Academic Experts, who have a broad understanding of disease and treatment.

TAIHO Mentorship Program

The Mentorship Program encourages the growth of young MRs using the skills and mature mindsets of experienced senior MRs. The program allows young MRs to accompany senior MRs beyond the branch where they are assigned. Learning the practical skills and creative methods of senior MRs leads to higher motivation among young MRs.

Employee Voice

As an in-house career counselor, I support employees who wish to explore their careers and understand themselves.




Akiko Shimizu
Human Resources

Conducting career training and offering individual consultations in the career counseling office, I try to support each employee to explore his or her future career vision. Together, we consider changes in the environment and make plans so each person can keep growing professionally throughout the decades. I always strive to foster an open culture where people can discuss their vision for the future with their supervisors and colleagues, and I help employees build careers that not only contribute to the organization but also provide a sense of accomplishment.

Developing Global Leaders: “Global One Academy” Corporate University

As Taiho Pharmaceutical actively expands its business globally, it is focusing on educating human resources ready to flexibly solve problems in cooperation with partners outside Japan. At the Global One Academy, established in 2016, members in their 20s and 30s spend a year learning the skills needed to develop into global leaders. Guest lectures and a unique curriculum that incorporates active learning are distinctive features of the corporate university.




Inspiring the Desire for Growth: Diverse Career Development Support Systems

To support employees’ desire to grow, companies must provide them with opportunities to think freely about their future vision. Taiho Pharmaceutical uses human resource development sheets and holds career development seminars where employees can pursue self-exploration. Meanwhile, the company has established a career consultation office supported by qualified in-house career counselor to create opportunities for employees to look five to ten years into the future. The company also provides assistance for correspondence course and for obtaining qualifications to support growth. A personal declaration system has been established to help employees take on the challenges of working in new fields or abroad.

GLOBALIZATION

Taiho Pharmaceutical's Future


Taiho Pharmaceutical is expanding its global reach, looking to become a specialty pharma trusted worldwide. The company conducts drug discovery R&D in collaboration with group companies in the U.S., Europe, and Asia. It is building its own marketing structures and expanding its sales network. In recent years, the company has established two corporate venture capital firms in order to expand its development pipeline and create innovation. Taiho Pharmaceutical aspires to make even greater contributions to medical care worldwide.



1  **TAIHO ONCOLOGY EUROPE GMBH**
Clinical development and marketing of pharmaceuticals in Europe

2  **TAIHO PHARMACEUTICAL OF BEIJING CO., LTD.**
Clinical development, product development, and promotional activities for pharmaceuticals in China

3  **TAIHO PHARMA ASIA PACIFIC PTE. LTD.**
Sales, regulatory affairs, and medical affairs in the Asia-Pacific region

4  **OKAYAMA TAIHO PHARMACEUTICAL CO., LTD.**
Manufacture and sale of topical products, authorized generics (AG*), and consumer healthcare products


5  **TAIHO INNOVATIONS**
Incubation and investment in Japanese startups


6  **TAIHO VENTURES, LLC**
Venture investment to support the creation of innovative cancer therapeutics

7  **TAIHO PHARMA CANADA, INC.**
Marketing of pharmaceuticals in Canada

8  **TAIHO ONCOLOGY, INC.**
Global clinical development and marketing of pharmaceuticals in the U.S.

*Authorized generics:
Generic drugs for which the use of patents, etc. has been authorized by the original manufacturer

 Learn more about global growth at Taiho Pharmaceutical



Message from EUROPE

Properly delivering Taiho Pharmaceutical's new drugs to patients from our new European base

Atsushi Azuma, Ph.D.

Chairman
TAIHO ONCOLOGY EUROPE GMBH



Taiho Oncology Europe was established in Zug, Switzerland in January 2021 to serve as the marketing company for the Taiho Group in Europe. By collaborating with other Otsuka group companies, we are currently building our own sales/marketing organization for the launch of the new oral anti-cancer agent futibatinib (development code: TAS-120), an FGFR inhibitor currently under development. Going forward, we hope to contribute to health and smiles for patients in Europe by promoting the proper use of our drugs and further expanding our lineup of anticancer drugs while strengthening our organization.

Message from ASIA

Aiming to deliver innovative new drugs to as many people in Asia as possible

Yoshimasa Nishimura

Managing Director
TAIHO PHARMA ASIA PACIFIC PTE. LTD.



Taiho Pharmaceutical of Beijing and Taiho Pharma Asia Pacific share the slogan, "By Local. For Local." Our primary mission is to provide the innovative new drugs and unique consumer healthcare products developed by Taiho Pharmaceutical to medical professionals, to patients, and to all the people of Asian countries and regions, through the caring hands of our local employees. Our entire team is united to give our best effort every day to bring smiles to the faces of as many locals as possible.

Message from NORTH AMERICA

Expanding our sales network from a global perspective and bringing Taiho Pharmaceutical's philosophy to the world

Timothy Whitten

President & CEO
TAIHO ONCOLOGY, INC.



Taiho Oncology has embraced the Taiho Pharmaceutical corporate philosophy and it guides us in every important decision we make. It helps us understand what we should do as we strive to improve human health and contribute to a society enriched by smiles. The corporate philosophy tells us we should expand commercially into other geographic markets, we should embrace globalization, and we should invest in our pipeline and marketed products globally. By doing that, it will allow more patients to benefit from our products, provide more financial resources to invest in our pipeline and marketed products development, and help the Taiho name become more well-known globally.




SUSTAINABILITY

Taiho Pharmaceutical's Future

Taiho Pharmaceutical's corporate philosophy, "We strive to improve human health and contribute to a society enriched by smiles," is the company's unchanging guideline for the future. Taiho Pharmaceutical's CSR mission is designed to ensure that the company's business activities help solve social and environmental issues. The company is working hard to help achieve the Sustainable Development Goals (SDGs) while promoting employee health, pursuing diversity and inclusion, and practicing optimal governance.










CSR Mission

As a member of the Otsuka group, Taiho Pharmaceutical has integrated CSR into its businesses and aims to achieve its own sustainable growth as well as healthy and sustainable societies enriched by smiles, in line with its corporate philosophy. We pursue these objectives supported by a comprehensive governance system.



 Healthier Society (Society) Health People Quality in all we do	 Healthier Planet (Environment) Climate change Resource circulation Water conservation
 Healthier Company (Governance) Corporate governance Compliance Risk management	

Taiho Pharmaceutical's Materialities and SDGs

Taiho Pharmaceutical is committed to doing its part in achieving the SDGs. As a company in the field of medical care, the company is focusing on the health and welfare-related targets. Meanwhile, it also aims to make broader social contributions and deliver business growth by helping to address social issues such as consideration for human rights and the environment. Here are some key objectives and achievements.

	<ul style="list-style-type: none"> ● Addressing unmet medical needs by strengthening versatile drug discovery capabilities ● Addressing medical needs related to cancer patients by improving access to information and treatment
	<ul style="list-style-type: none"> ● Endorsing the Women's Empowerment Principles (WEPs) as a member of the Otsuka Group
	<ul style="list-style-type: none"> ● Establishing goals for effective water resource use <p>KPI Water Use Efficiency 15% reduction by 2030 compared to 2017</p>
	<ul style="list-style-type: none"> ● Providing systems, environment, and education to allow employees with cancer and other illnesses to work while receiving treatment
	<ul style="list-style-type: none"> ● Establishing goals regarding waste <p>KPI Simple Incineration/Landfill 50% reduction by 2030 compared to 2017</p>
	<ul style="list-style-type: none"> ● Formulating an Otsuka group-wide procurement policy cognizant of human rights, labor, the environment, anti-corruption, etc.
	<ul style="list-style-type: none"> ● Establishing goals to reduce greenhouse gas emissions <p>KPI Greenhouse Gas Emissions 30% reduction (Scope 1+2) and 20% reduction (Scope 3) by 2030 compared to 2017</p>
	<ul style="list-style-type: none"> ● Integrating Japan-based drug discovery and global open innovation
	<ul style="list-style-type: none"> ● Compliance programs and compliance with related laws and regulations

Learn more about sustainability at Taiho Pharmaceutical

Healthcare Support Supporting People's Health in Many Ways



Supporting Cancer-Related Issues — Participating in the “READYFOR SDGs” Program

Taiho Pharmaceutical participated in the SDGs matching program, “READYFOR SDGs,” soliciting projects that address challenges in the field of oncology. For projects that achieved their target crowdfunding amount, Taiho Pharmaceutical matched the target amount, thereby supporting efforts to solve problems related to cancer that cannot be solved with medicines.



Supporting Patients and Caregivers — Expanding Support Outside Japan

Outside of Japan, Taiho Group companies collaborate with and support patient groups in the field of oncology. In particular, they focus on supporting patients and their caregivers, while conducting various awareness raising programs as well as educational and research-related activities and events.



Providing School Lunches to Developing Countries — TABLE FOR TWO Menus at Plants and Laboratories

Taiho Pharmaceutical's Tokushima Plant and Tsukuba Area, as well as Okayama Taiho Pharmaceutical, participate in the TABLE FOR TWO (TFT) program. The program provides school lunches to children in developing countries when people purchase TFT menu items at employee cafeterias.



Providing healthcare support

Social and Community Contribution Activities



Supporting Employees Creating Workplaces Where Everyone Can Work with Peace of Mind

Supporting Employees Who Need to Balance Work and Treatment Needs

For employees with cancer and chronic illnesses, Taiho Pharmaceutical has established work systems to balance work and treatment needs, including accrued paid time off, extended time off, remote work, and a reemployment system that allows employees to return to work.

Supporting Employee's Efforts to Quit Smoking and Develop Fitness Habits

Taiho Pharmaceutical is working to reduce smoking among employees to zero by 2023. It provides a subsidy for smoking cessation outpatient expenses and carefully enforces internal rules to protect people from passive smoking. The company also provides an exercise app to all employees to encourage fitness habits.

Operating an On-Site Daycare Center

Taiho Pharmaceutical has established a daycare center on the leafy grounds of the Tsukuba Area. A nurse is always on-site, and dinner is also provided during extended-hours childcare. The nursery is not limited to monthly childcare; it also offers temporary childcare for the children and grandchildren of employees. Taiho Pharmaceutical will continue to provide an environment where employees who are raising children can work with peace of mind.

Taiho Pharmaceutical is also enhancing diversity and inclusion through human resource development, balancing of work with childbirth and childcare, and health support initiatives that ensure that employees are able to work with vitality.




Diversity and Inclusion



Global Standard Quality Assurance

Taiho Pharmaceutical's four plants – the main Tokushima Plant, and the Kitajima, Saitama, and Inuyama plants – work together seamlessly on production. All of these plants implement thorough quality control in compliance with GMP* standards. The Tokushima, Kitajima, and Saitama plants in particular have met international standards, as attested to by inspections by U.S. and European authorities. With a responsibility to provide a stable supply of life-sustaining medicines, Taiho Pharmaceutical also takes steps to prepare for disasters. For the supply of anticancer drugs, the company has acquired ISO 22301, an international standard for business continuity management.

*GMP: Good Manufacturing Practice is a system for ensuring that products are consistently produced and controlled according to quality standards.



Employee Voice

Hoping to bring peace of mind and smiles to patients and their families with high-quality medicines



Yukihiro Dan, Ph.D.

Manager of Plant Quality Control

I have experienced firsthand the power of medical technology and pharmaceuticals to open the door to the future, when I almost lost my child to illness. Hoping to bring happiness to as many people as possible with Taiho Pharmaceutical's products, we are determined to continue providing high-quality medicines that patients can take with peace of mind through our quality assurance work, which includes building a world-class pharmaceutical quality system and managing its operations.



Main Products

Pharmaceutical Products

Learn more about pharmaceutical products



LONSURF Antitumor agent



TS-1 Antimetabolic agent



Abraxane Antitumor agent



UFT Antimetabolic agent



Bilanoa Antiallergic agent



Aloxi 5-HT₃ receptor antagonist antiemetic agent



TREMFYA Human anti-interleukin (IL)-23p19 monoclonal antibody

Consumer Healthcare Products

Learn more about consumer healthcare products



Tiovita Nutritive energy drink



Solmack Herbal digestive support drink



Harnicare Herbal medicine for mild incontinence and frequent urination



Pitas Sore throat relief strips

Efil Virus removal/antibacterial spray



Rismitas Food with function claims containing L-citrulline



Femilacto Food supplement containing mixed lactobacillus powder

A Promise from Taiho Pharmaceutical

Today and Every Day

Nothing feels so precious as the everyday

flowing along in the usual way.

Supporting the flow of your life is our work.

When the flow of your everyday life is lost,

we put all our power into helping you restore it

—Today and Every Day.

A promise from each one of us at Taiho Pharmaceutical.

The Thoughts That Inspire Everyone at Taiho

The flow of everyday life, with its familiar scenes and rhythms, is often taken for granted. It is often when people get sick, or become worried about the state of the world or their circumstances, that they finally realize the subtle value of everyday life.

Taiho Pharmaceutical must do more than cure diseases through its drug discovery. It is also our passion to give strength and to constantly support the precious moments of everyday life, helping to keep them flowing for all people, no matter what their health condition is.

As people in a business closely involved with human life, we ask ourselves: How deeply do we think about people's lives? How well do we understand the environment surrounding patients and their families? How much can we improve patients' quality of life? By considering everything from treatment to disease prevention, we hope to contribute to better health and bring smiles to as many people as possible.

Today and Every Day

This is a promise from, and the genuine wish of, each one of us working at Taiho. This is the story behind our communication slogan.

Today and Every Day



President's Message

Building Societies Enriched by Smiles with the Power of Pharmaceuticals — Doing What Needs to Be Done

Over all these decades, our employees have each thought about what it means for Taiho Pharmaceutical to do what needs to be done, and then acted accordingly. This is what drove us to develop a new oral anticancer drug at a time when oral anticancer drugs, which can be taken at home, were scarcely used. Ever since, we have powered our constant search for optimal methods of administration. Taiho Pharmaceutical is about to celebrate its 60th anniversary. Looking back on some of our history, it is clear that Taiho Pharmaceutical's growth has been supported by a culture where people persistently do what needs to be done, and passing the baton of that determination to their colleagues. We aim to keep growing by continuing to develop human resources who have the commitment and capacity to do what needs to be done.

"We...contribute to a society enriched by smiles" is a phrase that I especially value in our corporate philosophy. Working together with colleagues around the globe, our entire team will continue to deliver to the world high-quality, outstanding products that can be used with peace of mind. We will do our best to bring smiles to patients, indeed, to all people facing various problems, always helping to keep the rhythm of life flowing each and every day. I am confident that these efforts will enhance Taiho Pharmaceutical's presence as a valuable company that supports people's health and helps to build sustainable societies.

小林将之

Masayuki Kobayashi
President and Representative Director




Corporate Data

Company Name	TAIHO PHARMACEUTICAL CO., LTD.
Established	June 1, 1963
Capital	¥200 million
Representative	Masayuki Kobayashi, President and Representative Director
No. of Employees	2,246 (as of December 31, 2020)
Sales	¥140.1 billion (2020)
Net Income	¥15.2 billion (2020)
Offices	Head Office: Tokyo Branches: 15 in Japan for prescription drug sales 4 in Japan for consumer healthcare Offices: 50 in Japan Plants: 4 in Japan Laboratories: Tokushima and Tsukuba (Ibaraki)
Head Office Location	1-27 Kandanishiki-cho, Chiyoda-ku, Tokyo 101-8444, Japan TEL: +81-3-3294-4527

Management	
President and Representative Director	Masayuki Kobayashi
Senior Managing Director	Nobuyuki Hashimoto
Senior Managing Director	Teruhiro Utsugi
Senior Managing Director	Yasunori Okada
Executive Director	Tatsuya Niki
Executive Director	Atsushi Azuma
Standing Audit & Supervisory Board Member	Hiroki Yamashita
Outside Audit & Supervisory Board Member	Seiji Tsuji
Outside Audit & Supervisory Board Member	Yoshikatsu Nakashima

(As of March 31, 2021)

Net Sales
(FY2020)



<https://www.taiho.co.jp/en/>

Otsuka Group Corporate Philosophy

Otsuka-people creating new products for better health worldwide


Overview

The Otsuka group of companies, whose origins date back to 1921, aims to contribute to the health of people around the world. It aims to do so through two main pillars: the pharmaceutical business for the diagnosis and treatment of diseases and the nutraceutical*1 business to support the maintenance and promotion of everyday health.

The company's culture, summarized in a few words as, "Ryukan-godo" (by sweat we recognize the way), "Jissho" (actualization) and "Sozosei" (creativity), have been fostered by successive Otsuka leaders. These are emphasized by our 47,000*2 employees across 194 group companies in 32 countries and regions who strive to create and market unique products and services.

*1. Nutraceuticals: nutrition + pharmaceuticals *2. As of end of December, 2020. Otsuka Holdings and subsidiaries and affiliates.

Organizational Structure



Company Name	Otsuka Holdings Co., Ltd.
Established	July 8, 2008
President and Representative Director, CEO	Tatsuo Higuchi
Capital	81.69 billion yen
Head Office	2-9 Kanda-Tsukasamachi, Chiyoda-ku, Tokyo
Business Description	Strategic management and oversight of the group companies, and provision of specialized business services as a holding company of the group

CSR~For Sustainable Society~

[CSR Mission]

CSR is integrated into our businesses across the Otsuka group of companies, which aims to grow while contributing to the creation of a healthy and sustainable society. We pursue these objectives supported by a comprehensive governance system.

Contribution to a Sustainable Society



CSR is embedded in our businesses

Otsuka-people creating new products for better health worldwide



Otsuka Group 100th Anniversary

We will celebrate our 100th anniversary starting on September 1. This important milestone in our history will be a chance for all group employees to learn from our past and build towards our future as we strive to achieve the goals laid down in our corporate philosophy.



For more information about Otsuka Holdings : <https://www.otsuka.com/en/>
For more information about Otsuka group's CSR : <https://www.otsuka.com/en/csr/>





Today and Every Day

